Skip to main content

Table 1 Clinical characteristics of PB-DHL patients (n = 48)

From: Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience

Variable

DA-EPOCH-R/MA

(n, % )

DA-EPOCH-R

(n, % )

R-HyperCVAD

(n, % )

P value

Age

   

0.711

 ≤ 50 years

9 (64.3)

9 (50.0)

10 (62.5)

 

 50–60 years

5 (35.7)

9 (50.0)

6 (37.5)

 

Laterality

   

0.965

 Right

4 (28.6)

7 (38.9)

5 (31.3)

 

 Left

7 (50.0)

8 (44.4)

7 (43.8)

 

 Bilateral

3 (21.4)

3 (16.7)

4 (25.0)

 

Tumour size

   

0.811

 < 5 cm

8 (57.1)

11 (61.1)

11 (68.8)

 

 ≥ 5 cm

6 (42.9)

7 (38.9)

5 (31.3)

 

Cell of origin

   

0.890

 GCB

11 (78.6)

15 (83.3)

14 (87.5)

 

 Non-GCB

3 (21.4)

3 (16.7)

2 (12.5)

 

Results of FISH

   

0.745

 MYC-BCL2

10 (71.4)

15 (83.3)

13 (81.3)

 

 MYC-BCL6

4 (28.6)

3 (16.7)

3 (18.8)

 

C-MYC of IHC

   

1.000

 C-MYC (+)

14 (100.0)

18 (100.0)

16 (100.0)

 

BCL2 of IHC

  

0.521

 BCL2 (+)

13 (92.9)

18 (100.0)

15 (93.8)

 

BCL6 of IHC

   

0.767

 BCL6 (+)

14 (100.0)

16 (88.9)

15 (93.8)

 

CD5 of IHC

   

0.406

 CD5 (+)

5 (35.7)

4 (22.2)

7 (43.8)

 

CD10 of IHC

   

0.661

 CD10 (+)

10 (71.4)

10 (55.6)

9 (56.3)

 

P53 of IHC

   

0.926

 P53 (+)

9 (64.3)

13 (72.2)

11 (68.8)

 

Ki-67 of IHC

   

0.668

 Ki-67 ≥ 70 %

12 (85.7)

17 (94.4)

15 (93.8)

 

Chromosomal abnormality

   

0.700

 Present

3 (21.4)

6 (33.3)

3 (18.8)

 

Ann Arbor Staging

   

0.832

 IE

4 (28.6)

6 (33.3)

3 (18.8)

 

 IIE

7 (50.0)

7 (38.9)

7 (43.8)

 

 IV

3 (21.4)

5 (27.8)

6 (37.5)

 

B symptoms

   

0.652

 Present

10 (71.4)

10 (55.6)

10 (62.5)

 

LDH level

   

0.544

 Elevated

5 (35.7)

7 (38.9)

9 (56.3)

 

Risk stratification

   

0.665

  L and L-I

9 (64.3)

9 (50.0)

9 (56.3)

 

 H and H-I

5 (35.7)

9 (50.0)

7 (43.8)

 

ASCT

   

0.811

 Yes

6 (42.9)

7 (38.9)

5 (31.3)

 
  1. PB-DHL primary breast double-hit lymphoma, R-HyperCVAD rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, alternating with cytarabine plus methotrexate, DA-EPOCH-R rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, DA-EPOCH-R/MA rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, alternating with high-dose methotrexate and cytarabine, FISH fluorescence in situ hybridization, IHC immunohistochemistry, LDH lactate dehydrogenase, GCB germinal centre B-cell, L low risk, L-I low-intermediate risk H-I high-intermediate risk, H high risk, ASCT autologous stem cell transplantation